The lung tumors with lymphatic spreading were enriched with mutations in EGFR (P = 4E-03) and TP53 (P = 1.3E-02) (Table 2 and Fig. S5), indicating that tumors with EGFR or TP53 mutations were more likely to develop metastatic tumors and might have poorer prognosis. This evidence concerns the gene TP53 and metastatic neoplasm.